Breztri Aerosphere Reduced COPD Exacerbations Better Than Approved Therapies, Phase 3 Trial Shows
The triple combination therapy Breztri Aerosphere has successfully achieved its primary goal of reducing the rate of exacerbations — bouts of breathlessness — in people with chronic obstructive pulmonary disease (COPD) in the ongoing ETHOS trial, AstraZeneca announced.